Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Amivantamab monotherapy in relapsed/refractory metastatic colorectal cancer: OrigAMI-1, an open-label, phase 1b/2 study.
Authors
Paul Eliezer Oberstein
NYU Langone Health, New York, NY
Paul Eliezer Oberstein , Victor Moreno , Kanwal Pratap Singh Raghav , Yong Sang Hong , Sae-Won Han , Yu-Li Su , Ying Yuan , Filippo Pietrantonio , Eric Van Cutsem , Cathy Eng , Joshua C Curtin , Sanjib Chowdhury , Rianka Bhattacharya , Raymond Scott Maul , Ryota Iwasawa , Robert W. Schnepp , Roland Elmar Knoblauch , Meena Thayu , Gwo Fuang Ho , Han Sang Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05379595
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 135)
DOI
10.1200/JCO.2024.42.3_suppl.135
Abstract #
135
Poster Bd #
H20
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Marwan Fakih
Poster
2022 ASCO Annual Meeting
Open-label, dose-escalation, and expansion trial of CA-4948 in combination with ibrutinib in patients with relapsed or refractory hematologic malignancies.
First Author: Erel Joffe
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2014 ASCO Annual Meeting
STEAM: A randomized, open-label, phase 2 trial of sequential and concurrent FOLFOXIRI-bevacizumab (BEV) versus FOLFOX-BEV for the first-line (1L) treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Johanna C. Bendell